Stocks and Investing Stocks and Investing
Wed, January 5, 2022
Tue, January 4, 2022
Mon, January 3, 2022
Sun, January 2, 2022
Fri, December 31, 2021
Thu, December 30, 2021
Wed, December 29, 2021
Tue, December 28, 2021
Mon, December 27, 2021
Thu, December 23, 2021
Wed, December 22, 2021

Sumant Kulkarni Maintained (ACAD) at Hold with Increased Target to $30 on, Dec 22nd, 2021


Published on 2024-10-27 19:04:50 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $26 to $30 on, Dec 22nd, 2021.

Sumant has made no other calls on ACAD in the last 4 months.



There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 7 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $30 on, Tuesday, December 21st, 2021
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Increased Target to $32 on, Tuesday, December 21st, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
  • Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021


These are the ratings of the 2 analyists that currently disagree with Sumant


  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021
  • Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $42 on, Tuesday, December 21st, 2021